Medisan (Dec 2023)
Sensibility considering 2 concentrations of mite allergenic extracts
Abstract
Introduction: The Valergen® allergenic extracts (Dermatophagoides pteronyssinus, Blomia tropicalis and Dermatophagoides siboney), developed in the National Center for Biopreparations to use them in cutaneous tests to the patients with allergy, have demonstrated a high sensibility and specificity. Objective: To determine the sensibility considering 2 different concentrations of mite allergenic extracts by means of needle cutaneous tests. Methods: An observational, descriptive and cross-sectional study of 230 patients aged 5 to 49 was carried out. They were assisted in Ernesto Guevara de la Serna Teaching Polyclinic in Niquero, Granma province, during 2022. The analyzed variables were positive responses according to age, type of allergenic extracts, sensitization according to allergic diseases, as well as local adverse reaction. Results: In both concentrations, 20 000 UB/ml and 2000 UB/ml, there was a prevalence of the 5 to 13 age group (47.0%), the positive responses (27.8 and 25.7% for each dilution) and the Dermatophagoides pteronyssinus allergenic extract (93.9 and 89.1%, respectively). Rhinitis was the allergic disease with more sensitization (29.1 in the first concentration and 28.3% in the second one). The local adverse events were just presented in that of 20 000 UB/ml (3.9%) with an average wheal diameter of 15.9 mm (IC 95%: 15.4 – 16.4 mm) for the higher reaction. Conclusions: Mite allergenic extracts with a concentration of 2000 UB/ml were equally sensitive and safe than the established dilution of 20 000 UB/ml, which is recognized on a national scale by its quality as diagnosis method.
